Due to the limited number of drugs in current clinical use, the diverse biological applications of furan have encouraged the preparation of a wide variety of thiosemicarbazide and triazole derivatives for the purpose of developing new drug agents. This study aimed to investigate the antiproliferative and antioxidant activities of thiosemicarbazides (1–12) and 1,2,4-triazoles (13–24). Out of the synthesized target compounds, 3, 4, 6, 7, 8, 9, 10, 11, 12, 15, 16, 18, 19, 20, 21, 22, 23, and 24 are novel while the synthesis of the remaining compounds is present in the literature. Compound 15 (IC₅₀: 8.81 ± 0.28 µM) showed the highest antiproliferative activity against the cervical (HeLa) cancer cell line among the compounds. In the lipid peroxidation inhibitory activity, thiosemicarbazide derivatives 3, 10, and 9 showed highest activity with IC₅₀ of 21.80 ± 0.69, 26.49 ± 0.61, and 29.07 ± 0.52 µM, respectively, while triazole derivatives 15, 18, 19, 20, 21, and 22 exhibited the highest activity. Moreover, physicochemical properties, pharmacokinetic properties, and drug-likeness of all synthesized products were calculated using SwissADME. In addition, the effect of the structure–activity relationships of the 1,2,4-triazole derivatives (13–24) on the results of antiproliferative and antioxidant activity assays was evaluated.

由于目前临床使用的药物数量有限，呋喃的多样化生物应用促进了多种缩氨基硫脲和三唑衍生物的制备，以开发新的药物制剂。本研究旨在探讨氨基硫脲的抗增殖和抗氧化活性（1 - 12）和1,2,4-三唑（13 - 24）。在合成的目标化合物中，3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 15 , 16，18，19，20，21，22，23，和24是新的，而其余的化合物的合成中存在的文献中。化合物15 (IC ₅₀ : 8.81 ± 0.28 µM) 在化合物中对宫颈 (HeLa) 癌细胞系显示出最高的抗增殖活性。在脂质过氧化抑制活性中，氨基硫脲衍生物3、10和9表现出最高的活性，IC _{50 分别}为 21.80 ± 0.69、26.49 ± 0.61 和 29.07 ± 0.52 µM，而三唑衍生物15、18、19、20、21和22表现出最高的活性。此外，使用 SwissADME 计算了所有合成产品的理化特性、药代动力学特性和药物相似性。另外，1,2,4-三唑衍生物（的结构-活性关系的影响13 - 24）上的抗增殖和抗氧化活性测定法的结果进行评价。